RXRX
Recursion Pharmaceuticals Inc
Mentions (24Hr)
300.00% Today
Reddit Posts
5 moonshots I'm willing to hold through a 50% drawdown
If any of you investors go to the annual meeting of RXRX ask them why ALL THE INSIDERS are unloading their shares!
RXRX Monday Bearish Outlook: Data From Friday + Premarket Points to a Slide Watch
RXRX Bearish Outlook: I Think a New 52-Week Low Is Coming if $3 Breaks
Beyond the Hype: My "AI Meets Atoms" speculative basket
RXRX - Squeeze imminent, huge SI and massive call buying
RXRX Volume Update: Heavy Tape Again, But Bears Still Need the Break
RXRX: The $300M ATM Overhang Is the Part Bulls Should Not Ignore
RXRX Continuation: Yesterday Hit $3.50 — Now I’m Watching the Failed-Squeeze Retrace
RXRX Follow-Up: Still Watching for Breakdown, But Bulls Need to Defend This Level
RXRX Update: Yesterday’s Thesis Got Pushback — Here’s Where I Stand Today
RXRX Short Thesis Update: Why I Still Think $2.70 or Lower Is in Play
RXRX needs a investor relations firm to get the stock moving! They have ZERO!
NO INVESTOR RELATIONS FOR RXRX! Hire one so we investors can communicate with them!!!
Why my portfolio of small-cap calls is printing, and why I’m not selling yet (KEEL, PLUG, ACHR, RXRX)
RXRX ! Let’s not jump the gun on this stock!
How bad will the earnings be tomorrow of RXRX! Insiders continue to sell sell sell
Pharma AI - might still be too early
The former CEO has finally stepped down from RXRX and the CMO has also transitioned out. How do you investors feel about this?
First penny stock portfolio looking for feedback. (M) 31
$RXRX: The AI Bio-God of 2026 or Why You’re a Moron for Buying Overpriced Index Funds
Missed CVNA??? RXRX is Next 10 times play !! NOW !!
$RXRX at 52W lows, this isn’t investing, it’s a high-variance liquidity flip. Size it like a moonshot, not a compounder.
$RXRX: The “NVIDIA” of Biology is Sitting at a Massive Discount
Why I’m pivoting to TechBio $RXRX while everyone is distracted by the Powell investigation and $4600 Gold.
Recursion Pharmaceuticals (RXRX) Announces Positive Phase Results for REC-4881 - 43% median reduction in Polyps Burden - Pre-market up 7.01%
$QSI Waiting to see if there will be any filings after market on this Friday :) Hoping to see a $RXRX like move in 2023 if it is actually Nvidia.
Recursion Pharmaceuticals (RXRX) speaking at NVDA GTC with Eli Lilly
NVTS, Based on the recent history of NVIDIA's strategic investments in public companies, the chance is extremely high likely over 80-90%—that they have acquired a sub-5% stake in Navitas (NVTS). AMD must announce partnership asap, it's a fundamental enabler for the 800V DC architecture needed by AMD
Looks like November is for QSI (Quantum SI)🔥
💭 Quick 2-minute survey: Does financial literacy affect how much we invest?
💭 Quick 2-minute survey: Does financial literacy affect how much we invest?
Quantum-Si ($QSI) and EVIDENCE of why NVIDIA is the most compelling secret $50million investor. (FULL DD on the insane hype of this small-cap firm that had OVER 15-25million trade volume since LAST WEEK) (right after my initial post).
Quantum-Si ($QSI) and EVIDENCE of why NVIDIA is they're the most compelling $50million investor. (FULL DD on the insane hype of this small-cap firm that had OVER 15-25million trade volume since LAST WEEK) (right after my initial post).
$QSI again lol. Almost 25million in trade volume and Nvidia as rumored partner in the only PURE PLAY proteomic stock in this entire market.
$QSI again lol. Almost 25million in trade volume and Nvidia as rumored partner in the only PURE PLAY proteomic stock in this entire market.
$QSI again lol. Almost 25million in trade volume and Nvidia as rumored partner in the only PURE PLAY proteomic stock in this entire market.
RXRX about to Moon. Open style just added another $50k
Alphabet, Apple shares pop after judge rules that Google gets to keep Chrome
BTAI / RXRX / INOD – undervalued plays or just bagholder traps
Here’s my Magnificent 7 Small Cap v2:
RXRX is undervalued IMO and overly shorted (last post I'll make about this)
A big thank you to those who post great pics here
concerned about my current and future portfolio in the US
🧬 Recursion Pharmaceuticals (RXRX) – Deep Dive (as of June 7, 2025)
Mini windfall investment strategy.
Diversified biotech short portfolio - completely tweaked on naked short calls (-20 500$)
AI Drug Sector Mania Is Starting On FDA Announcement Of Replacing Animal Testing With AI-based models
AI Drug Sector Mania Is Starting On FDA Announcement Of Replacing Animal Testing With AI-based models
RXRX stock pop starts today after FDA shifts policy stance
insider trading made 500k filed with SEC should I buy puts?
Nvidia $NVDA has invested $50 million in Recursion Pharmaceuticals $RXRX, an AI drug discovery platform, which has sent its stock up by 78%
RXRX is my pick for the next big thing in AI, what are you betting on?
RXRX short interest only 11%, but a squeeze still playing out…
Insider Trading Weekly Update #028: $DASH CEO, CFO Dump Company Stock, Largest Trades Overall + By Market Sector From The Past Week
RXRX had prior support turned resistance and now we are coming back to that resistance again 29.50 area, just reclaimed 20 SMA will watch for the follow-through move and push over 29.50 and 37.00
RXRX had prior support turned resistance and now we are coming back to that resistance again 29.50 area, just reclaimed 20 SMA will watch for the follow-through move and push over 29.50 and 37.00
Mentions
RXRX might be my best buy of the year
Great info! RXRX is making me a killing today!
What do yall think about RXRX? It's 33% shorted and moving upwards through resistance...
I don't have enough karma in this channel to make a post but look at RXRX it's about to get squeezed
RXRX past the moon and goong to Mars
I think AI drug discovery is the next pump. RXRX
Specifically, RXRX, but there are a few worth looking at
RXRX breaking 200 day. Went in Friday small, hope for a pump & chump fomo session this week.
RXRX over 30% short interest with roughly 13 days for short sellers to cover at average volume. This lemon's looking for a squeeze.
This is such an obvious play, so undervalued... needs only 2 or 3 years to start realizing value... it's not going lower than this imo RXRX, HOVR, KOID all good
Just loading on RXRX everytime it moves.
$TEM - Up second day in a row but still undervalued Moderna's cancer vaccine was built on Tempus AI's Personalis ImmunoID NeXT Platform. On top of this: (1) $TEM: Tempus AI = largest biological and medical datasets with huge AI unlock potential. (2) $RXRX: Recursion Pharmaceuticals is anther one (huge biological and chemical datasets -> 50 petabytes of phenomics, transcriptomics, proteomics, ADME, and de-identified patient data). Here's Anthropic CEO's quote: [https://x.com/DarioAmodei/status/2088758819304443967](https://x.com/DarioAmodei/status/2088758819304443967) >Anthropic is ramping up its efforts very quickly in biology and medicine, and we hope to have incredible results in the coming years and some early glimmers in the coming months. When we’ve actually accomplished something real, the whole world will hear about it, as loudly as possible, you have my word on that. \-- Dario Amodei (Aug 15, 2026):
Who’s buying RXRX? 36.5% short
$TEM Moderna's cancer vaccine was built on Tempus AI's Personalis ImmunoID NeXT Platform. On top of this: (1) $TEM: Tempus AI = largest biological and medical datasets with huge AI unlock potential. (2) $RXRX: Recursion Pharmaceuticals is anther one (huge biological and chemical datasets -> 50 petabytes of phenomics, transcriptomics, proteomics, ADME, and de-identified patient data). Here's Anthropic CEO's quote: [https://x.com/DarioAmodei/status/2088758819304443967](https://x.com/DarioAmodei/status/2088758819304443967) >Anthropic is ramping up its efforts very quickly in biology and medicine, and we hope to have incredible results in the coming years and some early glimmers in the coming months. When we’ve actually accomplished something real, the whole world will hear about it, as loudly as possible, you have my word on that. \-- Dario Amodei (Aug 15, 2026):
Did my ALLO and RXRX go up just because of MRNA or do I have a chance here
Dealer gamma maps are genuinely useful for intraday scalps, but where I've found the real edge is combining that context with deep OTM LEAPS — StrikeEdge io flags those setups for me, and last week something like the RXRX calls went from $0.01 to $0.26. The gamma walls tell you **where** the market is pinned; the LEAPS play tells you **what** to do when it breaks. Curious whether your flow CVD has been predictive around those key gamma levels or mostly reactive?
Thank me later my list below 😄 (DYOR) 1. RXRX 2. CRCL 3. DVLT 4. BTQ 5. NVTS
My suggestion is to check on long-term value investing and keep a small portion of 5-10% for 100 baggers if one of the stock goes 100x you will gain so much worst case nothing to loose for 5-10% as your ETF should cover those in the years. So do some analysis and check some stocks. I'm thinking on a few at the moment: BTQ, RXRX , DVLT and CRCL. (DYOR)
RXRX is evaluated as the most realistic 100-bagger candidate because it combines an achievable starting market cap baseline with a physical data moat capable of capturing multi-billion dollar pharmaceutical software and royalty cash flows.
I'm planning on buying next 100 baggers RXRX, BTQ in my list anyone have good suggestions ?
I will give one 100 bagger possibility RXRX this is really awesome stock
Put the $1.50 into RXRX and and see what it can do
For example: * Caris Life Sciences (CAI) * Tempus AI (TEM) * Schrödinger (SDGR) * Recursion (RXRX)
Trying to buy back some RXRX calls that I sold last week, but this fucking shit is lagging I just want to close them for profit and peace of mind, but this thing won't let me :(
The $100/month problem is a position sizing issue, not a strategy issue. Deep OTM LEAPS let you run the same edge with asymmetric payoffs — RXRX calls at $0.01 going to $0.26 changes the math completely. I've been using StrikeEdge io to screen for those setups and it's shifted how I think about capital efficiency. Have you ever stress-tested your strategies against longer-dated low-premium plays?
Biotech is always long term. I have shares in RXRX and Prokidney. I already lost more than 50% that I’m running the wheel. It’s always a money loss until their clinical trials yield clinically significant results.
When is RXRX going to discover the cure for cancer with AI?
All beta is being demolished. RKLB, QS, TE, RXRX… market doesn’t care what sector.
Loaded on calls for SLS inAugust and ABSI and RXRX in January. Im going all-or-nothing ok biotechs
Check out $RPAY, $OXSQ, $NNOX, $RXRX, $LSF, $DDD, and $TVRD! Yeah, and $KOPN/$FABC!
CING, ACHV, RXRX, DRTS/DRTSW a million times, RVPH, CGTX
RXRX green on bloody thursday, imagine it on a pump day
RXRX is the worst choice in the pharma AI space. Dozens of better picks than it
RXRX continues its downward projectory with no end in sight! Shorts completely control this stock while ALL the insiders continue to sell! Jim Cramer said this is a horrendous stock that left a bad taste in his mouth!
One day RXRX will be the Palantir of biotechnology
Definitely not RXRX! The insiders are unloading their shares at a fast pace! No wonder the shorts are controlling them
Stay away from RXRX! A terrible stock with too much hype! Stock continues to head south!
The public examples (RXRX, which also bought peer Exscientia; SDGR) have not been good.
Maybe RXRX only because the former CEO and CMO are transitioning out finally!!
Zero-cost collar on SNDK makes sense given the run, but have you looked at whether the puts are rich enough to fully fund the calls at your target strike? After a move like that, IV on the downside can get skewed pretty hard. Been using StrikeEdge io lately to scan for mispriced LEAPS on momentum names — found some wild setups like a RXRX call that went from $0.01 to $0.26. Curious what expiry you're targeting for the collar legs?
Solid thesis — the enterprise refresh cycle for AI-capable hardware is real and massively underpriced by the market right now. NVDA and ARM LEAPS are worth watching hard here, especially deep OTM calls if you think this plays out over 12-18 months. I run setups like this through StrikeEdge io to filter for mispriced LEAPS before the volume picks up — caught a RXRX call go from $0.01 to $0.26 that way. The trick is positioning **before** the narrative becomes consensus. What's your timeline on the enterprise refresh wave?
There have already been hyped up names around AI drug discovery like RXRX; a name that I said a while ago that I thought was a short and wish I would have. "$CRSP, $NTLA, and $BEAM" All Ark-y names that have generally not traded that well over the last 5 years or so. I like investing in biotech, but don't own any of these. " $ILMN is building the infrastructure behind the industry," I'd rather own TMO than ILMN but life science has continued to be awful post-covid given overcapacity and other issues. I think AI would be particularly useful in terms of things like medical imaging - not long those names but that hasn't worked out well yet either - GEHC and the rest of medtech have had a lousy year. I'd like healthcare to be a more meaningful beneficiary of AI but I have yet to see the kind of meaningful progress I'd like. Most of it has been hype with little to show for it (rxrx)
Solid DD, ABCL is legitimately underreacted to for a binary event this size. Been running stuff like this through StrikeEdge io lately — it surfaces deep OTM LEAPS setups before they pop, caught a RXRX call that went from $0.01 to $0.26 last month. The asymmetry on a Phase 2 miss vs. hit here is exactly the kind of risk profile that prints on cheap calls. What strike and expiry are you eyeing?
Solid trade, classic deep OTM LEAPS setup on a quality pullback. Been running similar plays using StrikeEdge io to scan for mispriced deep OTM contracts — found a RXRX call at $0.01 that hit $0.26 recently. The key with these is exactly what you did: give it time and pick a name with strong fundamentals so the IV crush doesn't kill you. What was your exit target on the $120 strike?
RXRX. Former CEO and CMO are transitioning out! 2 brilliant professionals take over!
Vanguard and Blackrock are not buying into some thesis on RXRX. They are index trackers buying a portfolio allocation as that is their mandate to do. It literally means nothing with respect to performance expectations. Cathie Wood, lol Nvidia exited their position in the company, why do you think that is? Insiders are all selling as fast as they can and the CEO was forced out….. There might be a short squeeze about to happen, I have no idea but there is nothing healthy about this company or its prospects.
Yes had so it’s basically irrelevant now if not a bearish signal lol. I prefer ABCL for drug discovery companies but it’s already run up heavy. RXRX has potential but high risk.
$ABSI $RXRX new openai venture
I’m getting more confident that the **$300M ATM overhang is not just theoretical anymore**. RXRX is showing heavy pre-market activity with large blocks moving back and forth, and after yesterday’s squeeze to **$3.50**, this is exactly the kind of strength a company *could* use to quietly sell into the market. Not saying I can prove ATM shares are being sold in real time — we usually won’t know until later filings — but the setup is exactly why this overhang matters. If RXRX is using the bounce to raise cash, the stock could fade fast, and the 2024 dilution already showed this name can take a **double-digit hit** when equity supply hits the tape.
# RXRX Continuation: $3.50 Squeeze Failed, But Bears Still Need Confirmation 🐻 **Bearish / cautious short-term** 🐻 Ticker: **RXRX** Current setup: **failed-squeeze / pre-market hold watch** Bias: **bearish only if key levels break** Immediate resistance: **$3.48–$3.50** First support: **$3.44–$3.45** Breakdown trigger: **lose $3.40, then $3.25–$3.35** Main downside target: **$3.10 / $3.00 first, then $2.87–$2.80** Invalidation: **reclaim and hold above $3.50** Yesterday RXRX squeezed all the way to **$3.50**, and that move absolutely punished early shorts. But the key question today is whether that $3.50 move was a real trend reversal or just a squeeze into resistance. Pre-market is still elevated around the mid-$3.40s, so I’m not calling this a confirmed breakdown yet. What I’m watching: * **$3.48–$3.50** as immediate resistance * **$3.44–$3.45** as VWAP / EMA support * **$3.40–$3.41** as the first real downside test * **$3.25–$3.35** as the prior reclaim zone * **$3.10 / $3.00** as the larger breakdown levels The bear case is simple: If RXRX fails at **$3.50** again and loses **$3.44–$3.40**, yesterday’s move starts looking more like a failed squeeze than a real reversal. But if RXRX reclaims **$3.50** with volume, bears need to be careful because **$3.70–$3.75** and even **$4.00** can come into play. Fundamentally, the same split remains: 🔴 RXRX still has heavy cash burn and negative earnings. 🔴 The $300M ATM remains a dilution overhang. 🔴 Recent insider selling creates bad optics, even though it was under a 10b5-1 plan. 🔴 The stock is still trying to prove this is more than a relief bounce. 🟢 Cash runway into early 2028 is real. 🟢 Pipeline updates and partnership narratives can squeeze shorts fast. 🟢 Yesterday proved RXRX can move violently against crowded bearish trades. 🟢 Above $3.50, the short setup gets dangerous. My current view: **Bearish short-term only if RXRX loses $3.44–$3.40.** Until then, bears do not have full confirmation. Key level today: **$3.50** First bearish trigger: **lose $3.44 / VWAP** Cleaner confirmation: **lose $3.40** Major breakdown: **lose $3.10** Main target if breakdown confirms: **$3.00, then $2.87–$2.80** Invalidation: **hold above $3.50** Not financial advice. Watching whether yesterday’s $3.50 squeeze turns into continuation or fades back under VWAP.
does anyone else remember people shilling RXRX like 2 years ago. dead company
Ya, RXRX has found so many new discoveries.
A bunch of stuff I’m not invested in, but here’s some he has shared with me and keeps telling me to buy. - GCTS - SIMO - RXRX - GFS - LSCC - FLEX - MRVL (the only one of these I do have) For the record, he’s the one who told me about archer, rigetti, onds, kopn, pltr, ktos, and nbis, before I ever heard of them or seen them common on Reddit. All of those I bought and made good money on or I’m still currently holding.
**RXRX has negative EPS:** latest available data shows **EPS around -1.16** and negative P/E, which fits the cash-burn profile that tends to weigh on biotech/AI drug-discovery names.
Yeah, a decent chance biotech is the next phase of the AI play. I’ve got some nice positions in peptides/antibodies (ABCL/ABSI) and gene therapies (CRSP/BEAM/PRME). Also RXRX as a pure AI biotech play
Solid play, timing CCs after an earnings spike is always a guessing game. Rolling them out further if IV stays elevated could squeeze more premium out of the position. For the flip side, been using StrikeEdge io to find deep OTM LEAPS on volatile names like this — caught an RXRX call go from $0.01 to $0.26 recently. What strike did you sell the CCs at?
Biotech: ABCL, ABSI, GENB, RXRX
I saw Jensen say once that these incredibly difficult industries (he was comparing advanced computing to bio because it was at a RXRX town hall) have people who work on it and fail to breakthrough for decades, and it causes this feeling from the most experienced that breakthroughs are decades away, and then it’s new non-discouraged generation that comes in and the breakthroughs spark way faster than the industry expects. No idea if that happens here but it’s an interesting thought.
RXRX now has a chance to appreciate in value because Chris Gibson is leaving June 30 and so is David Mauro
RXRX this company is building revolutionary platform that possibly turn pharmaceutical around.
Your backtest results actually make total sense — early profit-taking cuts off the fat tail gains that make LEAPS worth holding in the first place. The whole edge is in asymmetry; you need those 500%+ runners to offset the losers, and rolling out early just bleeds theta twice. Been using StrikeEdge lately to screen deep OTM entries and the RXRX play I found there went from $0.01 to $0.26 — that kind of move only pays if you're still holding. What DTE and strike distance were you using in the tests?
First thing that comes to mind is RXRX, ai drug discovery. Too risky for me but I keep an eye on it and it could do a RKLB, also could do a space shuttle challenger.
Cheers all !! Not looking to dump 1000s in just a few notes to see if it returns as im approaching my share target in AUR. Any thoughts on Recursion Pharmaceuticals (RXRX)
[$RXRX](https://aimytrade.io/ticker/rxrx?utm_source=reddit&utm_medium=comment&utm_campaign=RobinHoodPennyStocks&utm_term=RXRX&utm_content=variant_1778007734850_hdb4d) is at $3. 35 into earnings, and my read is still cautious with bearish momentum at 60% confidence. I let the levels do the work instead of guessing, and with support sitting way down at $-1.
Officers at RXRX need to be terminated if the earnings are dismal once again!
$RXRX is at $3. 37 with bearish momentum at 60% confidence, so I’m less focused on the insider sells headline and more on whether price can stabilize after earnings. Could be wrong, but with biotech getting extra FDA attention today, I’d rather trade the reaction than guess, I mapped the current levels here: [$RXRX](https://aimytrade.io/ticker/rxrx?utm_source=reddit&utm_medium=comment&utm_campaign=RobinHoodPennyStocks&utm_term=RXRX&utm_content=variant_1777997211107_k8epu).
RXRX is crap. Tempus I can still understand.
I'm going to drop 10k into one of these next week. DD. Thoughts on which? MNKD, Keel, RXRX, GENI
Bold move converting $40k into deep OTM LEAPS — that's either genius or a margin call waiting to happen. The leverage can be insane though; been tracking setups on [StrikeEdge.io](http://StrikeEdge.io) and just watched an RXRX call go from $0.01 to $0.26 in days. The personal loan part is what's keeping me up at night for you. What strikes/expiries are you targeting?
Recursion Pharmaceuticals now has the chance to skyrocket north! Former CEO permanently leaving on June 30 replaced by the AMAZING Najat Khan who will lead RXRX to greatness and the CMO is also transitioning out to be replaced by the GENIUS Vikki Goodman! RXRX will one day be the Palantir of biotechnology
Bullfrog is in the early stage section RXRX is the hype BS play
most of these small AI bios are either way early or alot of hype like BFRG RXRX & a few others. also after the new RS & penny rules dropped on Jan 1 we are avoiding sub $1s they are not worth the trouble except for a few.
Fuck ya it is.. congratulations. Last week I made 200$ swinging Intel, SMR and RXRX ( very tiny positions) and never been happier. Losing all my money to bynd stock humbled me and now I'm following a very disciplined pattern.
Hope everyone knows the RXRX train is getting ready to leave the station. recent price predictions: $8-$11 Blackrock and JPMorgan own millions of shares purchased upwards of $5-$7 Current Price: $3.55 Me: A fucking idiot with a phone app
nvida partner with RXRX what happened it tanked
RXRX is worth watching closely here. Short interest remains elevated at roughly 37% of float, days to cover is high (10.6) and institutional ownership is meaningful (56%), which creates the ingredients for a potential squeeze if volume and a real catalyst show up. Not calling it a squeeze yet, but the setup is there and a breakout with confirmation could get interesting fast.
Losses only on short puts and calls alleviated by hedges. I am conflicted on realizing a loss on small RXRX and ANVX positions.
RXRX looks like it’s about to squeeze again but I already sold the kids
Got $4 calls so naturally RXRX will squeeze to $3.9999999
Not sure if my obscure nonsense threat worked but RXRX looks like it’s starting to squeeze
Squeeze RXRX to $5 or the owl gets it
RXRX up 5% since the open...I reiterate this stock is trading below $4 and is primed for a squeeze...